Muutke küpsiste eelistusi

E-raamat: Organoids for Preclinical Disease Modeling and Personalized Medicine

Edited by
Teised raamatud teemal:
  • Formaat - EPUB+DRM
  • Hind: 221,68 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Lisa ostukorvi
  • Lisa soovinimekirja
  • See e-raamat on mõeldud ainult isiklikuks kasutamiseks. E-raamatuid ei saa tagastada.
Organoids for Preclinical Disease Modeling and Personalized MedicineSuurem pilt
Teised raamatud teemal:

DRM piirangud

  • Kopeerimine (copy/paste):

    ei ole lubatud

  • Printimine:

    ei ole lubatud

  • Kasutamine:

    Digitaalõiguste kaitse (DRM)
    Kirjastus on väljastanud selle e-raamatu krüpteeritud kujul, mis tähendab, et selle lugemiseks peate installeerima spetsiaalse tarkvara. Samuti peate looma endale  Adobe ID Rohkem infot siin. E-raamatut saab lugeda 1 kasutaja ning alla laadida kuni 6'de seadmesse (kõik autoriseeritud sama Adobe ID-ga).

    Vajalik tarkvara
    Mobiilsetes seadmetes (telefon või tahvelarvuti) lugemiseks peate installeerima selle tasuta rakenduse: PocketBook Reader (iOS / Android)

    PC või Mac seadmes lugemiseks peate installima Adobe Digital Editionsi (Seeon tasuta rakendus spetsiaalselt e-raamatute lugemiseks. Seda ei tohi segamini ajada Adober Reader'iga, mis tõenäoliselt on juba teie arvutisse installeeritud )

    Seda e-raamatut ei saa lugeda Amazon Kindle's. 

Organoid technologies are preclinical models in which drug responses or radiotherapies are determined very closely to patient response. While until the recent past there were no three-dimensional systems in which the entire cellular content of an organ could be reflected, we can now create the physiological and structural features of an organ in vitro and model a disease effectively. As these diseases may be developmental defects, chronic diseases can also be investigated in detail at the gene and protein level with these systems. In terms of developmental biology, thanks to the use of organoids, it is possible to learn the physiological internal dynamics of organs and to model diseases other than cancer. Chapters include introductions to their respective topics, recent advancements and how future applications can be implemented to organoid models. Organoids for Preclinical Disease Modeling and Personalized Medicine serves as an aid to researchers working in this vital area of research.

Emerging roles of organoids in cancer research.- University of Greenwich.- Preclinical organoid models for modeling cancer.- Dana Farber Cancer Institute.- Prognostication of DNA repair inhibitor response in cancer organoids.- Ramya Ravindranathan.- Unraveling radiation response Insights from organoid systems.- Zeinaf Muradova.- Bladder organoids for healthy and diseased tissue modeling.- Dilara Akbulut.- Organoids to investigate immune functions immunological diseases and therapy.- Alexander Cicala.- Lymphoma organoid models for evaluating and targeting tumor immune microenvironment.- Sahin Lacin.- The use of organoids for modeling bone tumors and testing drugs.- Doruk Somuncu.- Lung organoids in disease modeling and treatment.- Organoid technology for brain disease modeling.- Deniz Altunsu Kurt.- Investigating pediatric diseases with organoid systems.- Fulden Aycan.- Engineering transplantable organoids for children with pediatric disorder.- Tansu Salman.- Organoid technology in cardiology for disease modeling and treatment.- Irem Turkmen.- Gastrointestinal organoids from pluripotent stem cells Jose Guillermo Sanchez Arriola Cincinnati Children Hospital Medical Center.- Brain organoids for unraveling human brain development and evolution.- Organoids for modeling skin hair pigmentation.- Proteomics applications on organoids to improve preclinical research.

ÖzgeSezin Somuncu is the Organoid Center Director and Senior Scientist in the Department of Radiation Oncology at DanaFarber Cancer Institute. Her research focuses on cancer biology, with special expertise in patientderived organoids, DNA damage and repair mechanisms (notably replication stress, USP1 and PARG pathways), and precision oncology. She earned her PhD from Yeditepe University and has held academic positions including Assistant Professor at Bahçeehir University. Her recent work has concentrated on identifying functional biomarkers for drug sensitivity in ovarian cancer models. She has authored numerous peerreviewed publications, contributed to patent applications, and currently leads collaborative translational projects aimed at improving therapeutic strategies. She currently leads and supports organoid-based translational research, oversees collaborative studies between lab researchers and clinicians and helps integrate organoids into preclinical drug development pipelines. 
Lisainfo e-raamatute kohta Lisainfo e-raamatute kohta
Püsilink: https://www.kriso.ee/db/97830321002456e.html